HK Stock Market Move | 160 HEALTH (02656) surged again by over 10% to a new high, with its stock price nearly doubling since its debut on March 9th.
Healthy 160 (02656) rose by over 10% again, reaching a high of 140.5 Hong Kong dollars, setting a new record high on the market. Since its listing on March 9, the stock price has nearly doubled.
160 HEALTH(02656) surged by more than 10%, reaching a high of HK$140.5, setting a new record high since its listing. The stock price has nearly doubled since its listing on March 9. Just a month ago, on February 11, the stock experienced a sharp drop of about 30%, but as of the time of writing, it has risen by 10.17% to HK$139.7, with a total trading volume of HK$1.27 billion.
In terms of news, 160 HEALTH recently announced that the board of directors has revealed positive progress in the group's digital healthcare solutions business until December 31, 2025. In the fiscal year 2025, the group has reached operational cooperation with 82 public second-class and above hospitals, under the name "160AI Hospital," representing an increase of over 720% compared to 2024. In the fourth quarter of 2025, 52 new cooperation agreements with public hospitals have been signed, achieving a sequential growth of 420%. Additionally, 160 HEALTH has announced the deployment of the "Medical Digital Employee" system for medical institutions, promoting the application of AI intelligent bodies such as OpenClaw in medical settings through an integrated model of "platform + AI intelligent body + operation."
It is worth noting that 160 HEALTH will face its first unlocking of shares next week. According to a previous announcement, Luo Holdings Limited (holding a 30.59% stake) will proceed with the unlocking of shares in two stages: the first stage unlocking deadline is March 16, 2026, and the final unlocking date is September 16, 2026.
Related Articles

GENSCRIPT BIO (01548) releases annual financial results, with a net loss attributable to shareholders of 533 million USD, a year-on-year shift from profit to loss.

SINOPEC SEG (02386) releases annual performance, shareholders' net profit of 1.798 billion yuan decreased by 27.1% year-on-year.

CITIC SEC: The impact of rising PET prices is controllable, and beverage companies are expected to reduce hedging costs.
GENSCRIPT BIO (01548) releases annual financial results, with a net loss attributable to shareholders of 533 million USD, a year-on-year shift from profit to loss.

SINOPEC SEG (02386) releases annual performance, shareholders' net profit of 1.798 billion yuan decreased by 27.1% year-on-year.

CITIC SEC: The impact of rising PET prices is controllable, and beverage companies are expected to reduce hedging costs.






